RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Lactate as a Signaling Molecule in the Tumor Microenvironment: Implications for Cancer Progression.
Lactate as a Signaling Molecule in the Tumor Microenvironment: Implications for Cancer Progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
有氧糖酵解是肿瘤细胞常用的一种过程,用于产生过量乳酸、使细胞外环境酸化并促进肿瘤进展。乳酸在肿瘤微环境(TME)中既作为代谢中间产物,也作为信号分子发挥作用。在这篇文献综述中,我们首先描述癌细胞如何改变其代谢,重点关注Warburg效应、LDHA介导的乳酸催化以及MCT1/4在乳酸清除中的作用。接下来,我们解释GPR81介导的信号转导以及对HIF-1α和NF-κB降解的抑制,这将代谢与致癌信号通路联系起来。
我们讨论乳酸驱动的组蛋白乳酰化作为一种表观遗传过程,可增强与生长、血管生成和免疫逃逸相关的基因表达。我们还考察乳酸对免疫细胞的影响,包括抑制CD8 + T细胞和NK细胞、促进巨噬细胞向M2表型极化,以及抑制树突状细胞(DC)成熟。乳酸在癌相关成纤维细胞与肿瘤细胞之间的穿梭促进代谢共生和治疗耐药。
最后,本综述考察靶向LDH和MCT的治疗选择,无论是单独使用还是与免疫治疗联合使用。我们还讨论包括代偿性通路激活和脱靶效应在内的挑战。理解乳酸对TME作用的机制有助于开发更有效的代谢和免疫代谢癌症治疗。从临床角度看,通过LDHA抑制剂和MCT阻断剂靶向乳酸代谢,单独使用或与免疫检查点抑制剂联合使用,代表了一种有前景的策略,可重塑免疫抑制性TME并改善治疗结局。
然而,代谢可塑性、通路冗余以及肿瘤选择性不足仍是重要的转化挑战,值得进一步研究。
Aerobic glycolysis is a process commonly utilized by tumor cells to produce excessive lactate, acidification of the extracellular milieu and promoting tumor progression. Lactate plays its roles as a metabolic intermediate and as a signaling molecule in the tumor microenvironment (TME).
In this literature review, we first describe how cancer cells alter their metabolism, focusing on the Warburg effect, LDHA-mediated lactate catalysis, and MCT1/4's role in its removal. Next, we explain GPR81-mediated signal transduction and inhibition of HIF-1α and NF-κB degradation, which connects metabolism to oncogenic signaling pathways.
We discuss lactate-driven histone lactylation as an epigenetic process that enhances gene expression for growth, angiogenesis, and immune evasion.
We also examine lactate effects on Immune cells by inhibition of CD8 + T and NK cells, macrophage polarization toward the M2 phenotype, and inhibition of dendritic cell (DC) maturation. Lactate shuttling between cancer-associated fibroblasts and tumor cells promotes metabolic symbiosis and therapy resistance. Lastly, this review examines treatment options targeting LDH and MCTs, either on their own or in combination with immunotherapy.
We also discuss challenges including compensatory pathway activation and off-target effects. Understanding the mechanisms of lactate 's effects on the TME facilitates the development of more effective metabolic and immunometabolic cancer treatments. From a clinical perspective, targeting lactate metabolism through LDHA inhibitors and MCT blockers, alone or combined with immune checkpoint inhibitors, represents a promising strategy to recondition the immunosuppressive TME and improve therapeutic outcomes.
However, metabolic plasticity, pathway redundancy, and insufficient tumor selectivity remain significant translational challenges that warrant further investigation.
MEMBER ACCOUNT
登录成功会直接打开下一页。